OrthoSensor is trying to bring a data-driven revolution to orthopedics. It is building a three-legged platform, with intelligent instruments, intelligent implants, and analytics, all driven by sensor and other micro-electronics technology that feed back to surgeons vital data both intra- and post-operatively. Critical to its strategy: that improving outcomes in orthopedic surgery rests on developing better, data-rich surgical techniques, rather than novel implants made of new materials or design features.
by David Cassak
It would be misleading to say that orthopedic surgeons, up to their elbows in blood and bone, don't really know...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.
Medtronic held its grip on first place in the 2024 global medical device and diagnostics rankings after losing it two years ago to Abbott, which is now in third place behind fast-rising, acquisitive Johnson & Johnson MedTech.
A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.
